FDA accepts Revolution Medicines' NDA for daraxonrasib for pancreatic cancer

NDA FilingdaraxonrasibPositive

AI Analysis

Summary

Revolution Medicines' NDA for daraxonrasib in pancreatic cancer has been accepted by the FDA. This acceptance allows the application to proceed for regulatory review toward potential approval.

Outcome Details

FDA accepts NDA

Importance:7/10

Sentiment:

0.70

FDANDA acceptanceoncologypancreatic cancerdaraxonrasib

Related Companies

$RVMD

Read the original article

Published by Seeking Alpha Healthcare on July 22, 2026 8:27 PM

Read Original